In this episode of Talking Head Pain, Joe is joined by Dr. Andrew Charles, Professor of Neurology and Director of the UCLA Migraine and Pain Program, as well as the current President of the American Headache Society (AHS). Together, they explore the groundbreaking updates in migraine prevention therapy, highlighting the AHS's recent position on CGRP inhibitors as a first-line treatment. Dr. Charles shares insights into the development of these migraine-specific therapies, their efficacy, and the significant impact they have on patients' lives, offering a glimpse into the future of migraine management. 

Join Joe and Dr. Charles for a compelling conversation that shines a light on the latest advancements in migraine treatment and the positive changes they bring to the migraine community.

For more information, visit: https://ghlf.org/migraine/ahs-recommends-cgrp-therapies/ 

Contact Our Hosts:

Joe Coe, Director, Therapeutic Area Growth and Integration at GHLF: jcoe@ghlf.org

Sarah Shaw, Senior Manager of BIPOC Community Outreach at GHLF: sshaw@ghlf.org

A podcast episode produced by Ben Blanc, Manager of Programs & Special Projects at GHLF.

We want to hear what you think. Send your comments, or a video or audio clip of yourself, to podcasts@ghlf.org  

Catch up on all our episodes on our website or on your favorite podcast channel.